Prognostic analysis of primary gastrointestinal diffuse large B-cell lymphoma
10.3760/cma.j.issn.0254-1432.2010.09.011
- VernacularTitle:原发胃肠道弥漫性大B细胞淋巴瘤的预后分析
- Author:
Chenli ZHANG
;
Ji ZHANG
;
Junmin LI
;
Jie ZHONG
;
Shihu JIANG
- Publication Type:Journal Article
- Keywords:
Lymphoma,large B-cell,diffuse;
Chemotherapy;
Surgical intervention;
Prognosis
- From:
Chinese Journal of Digestion
2010;30(9):614-618
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the clinical characteristics of primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL) and its treatment and prognosis. Methods Twenty patients diagnosed with PGI-DLBCL were admitted to hospital between 2003 and 2007. The clinical characteristics and tumor molecular model of PGI-DLBCL as well as therapeutic methods were retrospectively studied. The factors that related to survival and prognosis were statistically analysed.Results The overall survival (OS) time of the patients were from 42 months to 52 months,while the progression-free survival (PFS) time were from 37months to 47 months. The International Prognostic Index (IPI) score (0～2 or ＞2) played a reminding role in prognosis of the disease. Tumor molecular model was no effect on prognosis [that was no significant difference between germinal center B-cell-like (GCB) type and non-GCB type]. The efficacy of Rituximab in combination with CHOP chemotherapy (R-CHOP) in treatment of PGI-DLBCL was similar to CHOP chemotherapy alone, whereas surgical intervention might prolong survival period. Conclusions The biological characteristics of PGI-DLBCL is so particular that the most therapeutic method, which need to be further studied, would be different from DLBCL in other position.
